Knockdown of YAP/TAZ sensitizes tamoxifen-resistant MCF7 breast cancer cells

• DOI: 10.1016/j.bbrc.2022.02.083
• Publication Date: 2022-02-23T08:23:57Z
• Authors: Yu Jin Kim; Se-Kyeong Jang; Sung-Eun Hong; Chan Sub Park; Min-Ki Seong; Hyun-Ah Kim; Ki Soo Park; Chun-Ho Kim; In-Chul Park; Hyeon-Ok Jin
• Keywords: Survivin

Although endocrine therapy with tamoxifen has improved survival in breast cancer patients, resistance to this remains one of the major causes mortality. In present study, we found that expression level YAP/TAZ tamoxifen-resistant MCF7 (MCF7-TR) cells was significantly increased compared cells. Knockdown siRNA sensitized MCF7-TR tamoxifen. Furthermore, targeting PSAT1, a downstream effector YAP/TAZ, enhanced sensitivity Additionally, mTORC1 activity and survivin were decreased during cell death induced by combination treatment or PSAT1 conclusion, YAP/TAZ-PSAT1 axis could sensitize modulating mTORC1-survivin axis.